VivoSeq
Cardiovascular

Vascular Inflammation

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Vascular Inflammation is an early-stage landscape with 0 programs across 1 company. The most active players are Tallikut Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Tallikut Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed8 · 53%
Withdrawn2 · 13%
Recruiting2 · 13%
Unknown status2 · 13%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

15 trials

Canagliflozin Targeting Vascular Inflammation
Recruiting·OOttawa Heart Institute Research Corporation·Phase 2/3·NCT05427084·24 enrolled
Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study
Recruiting·—·N/A·NCT06427694·60 enrolled
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Not yet recruiting·MMassachusetts General Hospital·Phase 2·NCT06691217·120 enrolled
Effect of Celecoxib on Markers of Vascular Inflammation
Completed·UUniversity of Florida·Phase 4·NCT00471341·75 enrolled
Study Effect of VIA-2291 on Vascular Inflammation
Completed·TTallikut Pharmaceuticals, Inc.·Phase 2·NCT00358826·191 enrolled
Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes
Completed·SSteno Diabetes Center Copenhagen·Phase 4·NCT03449654·102 enrolled
Colchicine in Vascular Inflammation Assessed With PET Imaging
Completed·MMontreal Heart Institute·Phase 2·NCT02162303·106 enrolled
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Completed·IIcahn School of Medicine at Mount Sinai·Phase 3·NCT02576067·123 enrolled
Cardiovascular Inflammation Reduction Trial
Completed·—·Phase 3·NCT01594333·4,786 enrolled
YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering
Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT01837823·91 enrolled
TransIent Perivascular Inflammation of the Carotid Artery (TIPIC) Syndrome: Clinical and Radiological Follow-up
Completed·FFondation Ophtalmologique Adolphe de Rothschild·N/A·NCT03804112·47 enrolled
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
Withdrawn·SStanford University·Phase 2·NCT02995642
Vascular Inflammation and Cholesterol Lowering Therapy
Withdrawn·—·Phase 4·NCT02941016
Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue
Unknown status·KKurume University·Phase 4·NCT02996916·100 enrolled
Colchicine Effect on Perivascular Inflammation Index on Coronary CTA
Unknown status·UUniversity of Sao Paulo General Hospital·Phase 1·NCT05347316·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)